ABRS with Purulent Nasal Discharge: When Amoxicillin Therapy Fails to Improve Symptoms

This protocol applies to patients with uncomplicated acute bacterial rhinosinusitis (ABRS) and no penicillin allergy whose symptoms have not improved as expected on a first-line amoxicillin-based regimen.

Clinical Scenario

ABRS is diagnosed when purulent nasal drainage, accompanied by nasal obstruction and/or facial pain-pressure-fullness, persists without improvement for at least 10 days — or worsens within 10 days after initial improvement (double worsening). The infection is uncomplicated: there is no neurologic, ophthalmologic, or soft-tissue extension beyond the paranasal sinuses and nasal cavity.

Previous Treatment — Goal Not Met

The patient has already received first-line amoxicillin (with or without clavulanate). Signs and symptoms of ABRS should generally improve within 3 to 5 days after initiating antibiotic therapy. When that improvement does not occur, escalation to the next antibiotic step is indicated.

Next-Step Approach

When ABRS is confirmed and first-line amoxicillin-based therapy has not produced the expected response, the recommended approach involves changing to an alternative antibiotic agent. The specific agent, dosing, and selection criteria are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/ohn.1344

A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening).

Uncomplicated rhinosinusitis is defined as rhinosinusitis without clinically evident extension of inflammation outside the paranasal sinuses and nasal cavity at the time of diagnosis (e.g., no neurologic, ophthalmologic, or soft tissue involvement).

If ABRS is confirmed, the clinician should change the antibiotic.

Optimal therapy of multi-drug resistant S. pneumoniae and beta-lactamase-producing H. influenzae and M. catarrhalis, would include high-dose amoxicillin-clavulanate (4 g per day amoxicillin equivalent) or a respiratory fluoroquinolone (ie, levofloxacin, moxifloxacin,) if no alternative agents are available.

View source ↗